Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan

Keyphrases

• Taiwan 100%
• Cost-effectiveness 100%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Docetaxel 100%
• Immune Checkpoint Inhibitors 100%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Clinical Outcomes 66%
• Nivolumab 66%
• Pembrolizumab 66%
• Quality-adjusted Life Years 66%
• Life-years Gained 66%
• Atezolizumab 66%
• High Cost 33%
• National Health Insurance 33%
• Previously Treated 33%
• Mean Survival Time 33%
• Tertiary Hospital 33%
• Second-line Treatment 33%
• Markov Model 33%
• Randomized Clinical Trial 33%
• Claims Data 33%
• Willingness-to-pay Threshold 33%
• Probabilistic Sensitivity Analysis 33%
• One-way Sensitivity Analysis 33%
• Incremental Cost-effectiveness Ratio 33%
• Incremental Cost 33%
• Clinical Costs 33%
• Drug Acquisition Cost 33%
• Health Resource Use 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Immune Checkpoint Inhibitor 100%
• Docetaxel 75%
• Pembrolizumab 50%
• Nivolumab 50%
• Atezolizumab 50%
• Immunotherapy 25%
• Base 25%
• Randomized Clinical Trial 25%